The discovery of a new antibiotic has brought fresh hope that a looming health crisis caused by drug resistant infections can be avoided. Called teixobactin, it is the result of a private public collaboration involving universities in the US and Germany, and the US biotech company NovoBiotic pharmaceuticals. Andrew Ward, pharmaceuticals correspondent, talks to Clive Cookson, science editor, about the discovery.

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on News in Focus when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast